In line with this guidance, the proposed study design includes a comparison to females aged 15 to 25 years i.e. in the age range for which high efficacy had been demonstrated following a 3-dose schedule.
In line with this guidance, the proposed study design includes a comparison to females aged 15 to 25 years i.e. in the age range for which high efficacy had been demonstrated following a 3-dose schedule.